Neumora Therapeutics, Inc.

NMRA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
42
SEC Filings

Business Summary

PART I ITEM 1. B usiness. Overview We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. We are advancing a Phase 3 progra...

Next Earnings

Q2 FY2026 — expected 2026-08-05

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNMRAdiscussed_in_filing Cybersecurity
topic_mentionNMRAdiscussed_in_filing Cybersecurity
topic_mentionNMRAdiscussed_in_filing Healthcare & Bio
topic_mentionNMRAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001193125-26-130388EDGAR94K words
2025-03-032024-12-310000950170-25-030401EDGAR—
2024-03-072023-12-310000950170-24-027927EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269446EDGAR71K words
2025-08-062025-06-300000950170-25-104138EDGAR—
2025-05-122025-03-310000950170-25-069311EDGAR—
2024-11-122024-09-300000950170-24-125437EDGAR—
2024-08-062024-06-300000950170-24-091737EDGAR—
2024-05-072024-03-310000950170-24-054448EDGAR—
2023-11-012023-09-300000950170-23-057424EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001193125-26-130372EDGAR3K words
2026-02-110001193125-26-045526EDGAR—
2026-01-120001193125-26-009727EDGAR—
2026-01-050001193125-26-001472EDGAR—
2025-11-210001193125-25-291352EDGAR—
2025-11-060001193125-25-268046EDGAR—
2025-10-270001193125-25-250677EDGAR—
2025-10-270001193125-25-250656EDGAR—
2025-08-060000950170-25-103997EDGAR—
2025-05-300001193125-25-132307EDGAR—

42 total filings indexed. 22 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001885522
TickerNMRA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c51451fec5b317c635ab7bb6e419ce41d81b91bc78f3d22174f1f71e03d3a5d7
parent: 97528e078b9adb2cedb9f8b41aedd88b3097a55e2b0bbb97c0777d4382694af8
content hash: f3563606205ab28d8478a3fc4d93393ceb0ec9659610eecbc943c0c5d2e652be
signed: 2026-04-13T04:46:32.128Z
sources: 10 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf